Details for Patent: 8,586,597

Title:	6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
Abstract:	Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform PI3K.delta. activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below. ##STR00001##
Inventor(s):	Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA)
Assignee:	ICOS Corporation (Indianapolis, IN)
Filing Date:	Dec 27, 2012
Application Number:	13/728,807
Claims:	1. A compound, wherein the compound is ##STR00184## or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable excipient. 4. The pharmaceutical composition of claim 3, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof. 5. A kit comprising the compound according to claim 1. 6. The kit according to claim 5, wherein the compound is the S-enantiomer, or a pharmaceutically acceptable salt thereof.